Edition:
United States

BioCryst Pharmaceuticals Inc (BCRX.O)

BCRX.O on Nasdaq

5.51USD
2 Dec 2016
Change (% chg)

$0.34 (+6.47%)
Prev Close
$5.18
Open
$5.19
Day's High
$5.51
Day's Low
$5.18
Volume
693,520
Avg. Vol
974,865
52-wk High
$10.98
52-wk Low
$1.63

Summary

Name Age Since Current Position

George Abercrombie

61 2013 Non-Executive Independent Chairman of the Board

Jon Stonehouse

54 2007 President, Chief Executive Officer, Director

Thomas Staab

70 2013 Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer

Yarlagadda Babu

62 2013 Senior Vice President - Drug Discovery

Lynne Powell

48 2015 Senior Vice President, Chief Commercial Officer

William Sheridan

60 2008 Senior Vice President, Chief Medical Officer

Alane Barnes

49 2013 Vice President, General Counsel, and Corporate Secretary

Fred Cohen

59 2013 Director

Robert Ingram

73 2015 Director

Sanj Patel

46 2015 Director

Stanley Erck

67 2008 Independent Director

Nancy Hutson

65 2012 Independent Director

Kenneth Lee

68 2011 Independent Director

Rob Bennett

Vice President Investor Relations & Operations

Biographies

Name Description

George Abercrombie

Mr. George B. Abercrombie is Non-Executive Independent Chairman of the Board of BioCryst Pharmaceuticals, Inc. Mr. Abercrombie was appointed to the Board in October 2011. Mr. Abercrombie has over 30 years of experience as a business leader in the pharmaceutical industry. He most recently served from 2001 to 2009 as the President and Chief Executive Officer of Hoffmann-La Roche Inc., a pharmaceutical company, where he was responsible for operations in both the U.S. and Canada. During his tenure, Mr. Abercrombie also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. In 1993, Mr. Abercrombie joined Glaxo Wellcome Inc. as Vice President and General Manager of the Glaxo Pharmaceuticals Division, and was later promoted to Senior Vice President, U.S. Commercial Operations. Prior to joining Glaxo, he spent over ten years at Merck & Co., Inc., where he gained experience in sales and marketing, executive sales management and business development. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill, and later earned an MBA from Harvard University. Mr. Abercrombie currently serves as a member of the Board of Directors of Tranzyme Pharma and as Chairman of the Board of Brickell Biotech and formerly served on the Boards of Directors of Inspire Pharmaceuticals, Inc. and Ziopharm Oncology, Inc. Additionally, he is Vice-Chairman of the Board of Directors of Project HOPE and a Senior Scholar at Duke University’s Fuqua School of Business. He previously served on the Executive Committee and Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA), as well as on the Board of the Johns Hopkins School of Hygiene and Public Health.

Jon Stonehouse

Mr. Jon P. Stonehouse is President, Chief Executive Officer, Director of Biocryst Pharmaceuticals Inc. He joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers and acquisitions, global licensing and business development, corporate strategy and alliance management. In March of 2002, Mr. Stonehouse was appointed Vice President of Global Licensing and Business Development and Integration, where he was responsible for the worldwide licensing and business development activities for the Ethical Pharmaceutical Division of Merck KGaA. Mr. Stonehouse joined EMD Pharmaceuticals, Inc. (the US Ethical Pharma division for Merck KGaA) in December 1999 as Vice President, Licensing and Business Development—Strategy & Integration and IT. Prior to joining Merck KGaA, he held a variety of roles at Astra Merck/AstraZeneca including: Customer Unit Director, Director, Marketing & Sales—IT, National Sales Manager, National Sales Director—Managed Healthcare, and Product Director—Omeprazole (the world’s most widely prescribed prescription drug at that time). Mr. Stonehouse started his career in the pharmaceutical industry as a Sales Representative, National Sales Trainer and District Sales Manager for Merck & Co., Inc. In November 2008, Mr. Stonehouse joined the Advisory Board of Precision Biosciences, Inc., a private biotechnology company. Mr. Stonehouse earned his BS in Microbiology at the University of Minnesota.

Thomas Staab

Mr. Thomas R. Staab, II, is Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer of BioCryst Pharmaceuticals, Inc. Thomas joined BioCryst in July 2011 as its Chief Financial Officer and Treasurer. Mr. Staab most recently served as Executive Vice President, Chief Financial Officer and Treasurer of Inspire Pharmaceuticals from May 2003 through its $430 million acquisition by Merck & Co., Inc. in May 2011. Prior to joining Inspire, he held senior financial positions of acting Chief Financial Officer and Treasurer at Triangle Pharmaceuticals, Inc. through its $480 million acquisition by Gilead Sciences, Inc. in 2003. Before joining Triangle, Mr. Staab spent eight years working for PriceWaterhouseCoopers LLP providing audit and business advisory services to national and multi-national corporations in the biotechnology, pharmaceutical, pulp and paper and communications industries. Mr. Staab currently serves on the Executive Committee of the Board of Directors of the North Carolina Biosciences Organization (“NCBIO”) and is a member of its Audit Committee. He has received several awards for his contribution and leadership to other organizations through NCBIO. He is a Certified Public Accountant and received a B.S. in Business Administration and a Masters of Accounting from the University of North Carolina at Chapel Hill.

Yarlagadda Babu

Dr. Yarlagadda S. Babu, Ph.D., is Senior Vice President - Drug Discovery of the company since October 2013. Dr. Babu was the Vice President - Drug Discovery of Biocryst Pharmaceuticals Inc. He joined BioCryst in 1988 and was BioCryst’s first full-time employee. Dr. Babu has served as the Company’s Vice President — Drug Discovery since 1992. Prior to joining BioCryst, he served five years on the biochemistry faculty at the University of Alabama at Birmingham.

Lynne Powell

Ms. Lynne Powell has been appointed as Senior Vice President, Chief Commercial Officer of the Company effective January 26, 2015. Ms. Powell brings 24 years of industry experience to BioCryst. Most recently she served as Senior Vice President of North American Commercial Operations at CSL Behring. In this role, she was accountable for the financial performance and general management of CSL Behring's commercial activities within the U.S. and Canada. Throughout her 17 year career at CSL Behring, Ms. Powell assumed increasing responsibilities within the R&D, and commercial functions of the organization. She has significant global experience gained as Vice President, Global Commercial Development and Head of Business Development & European Marketing. Ms. Powell launched five products globally for rare diseases, including hereditary angioedema (HAE). Prior to CSL, she held positions of increasing responsibility within GlaxoWellcome's commercial strategy and clinical research organizations.

William Sheridan

Dr. William P. Sheridan is Senior Vice President, Chief Medical Officer of Biocryst Pharmaceuticals Inc. Dr. Sheridan joined BioCryst in July 2008 as its Senior Vice President and Chief Medical Officer. Dr. Sheridan spent 15 years in drug development at Amgen Pharmaceuticals, Inc., most recently as Vice President of North American Medical Affairs from March 2007 to November 2007, prior to joining the Company. Dr. Sheridan organized and led Amgen’s U.S. Medical Affairs function, making contributions to the launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®. In addition to his most recent position at Amgen, Dr. Sheridan served at the Vice President level in International Medical Affairs, from March 2005 to February 2007; Global Health Economics, from January 2004 to January 2005; and Outcomes Research, U.S. Medical Affairs and Product Development from January 2002 to December 2003. Prior to joining Amgen, Dr. Sheridan practiced medicine at the Royal Melbourne Hospital in Victoria, Australia as Head of the Bone Marrow Transplant Service. He earned his MBBS degree (M.D. equivalent) at the University of Melbourne in Victoria. He is a board-certified fellow of the Royal Australasian College of Physicians, with a sub-specialty in hematology and medical oncology. After leaving Amgen in November 2007 and prior to joining the Company, Dr. Sheridan served as an independent consultant for pharmaceutical companies, including BioCryst.

Alane Barnes

Ms. Alane P. Barnes is the Vice President, General Counsel, and Corporate Secretary of BioCryst. She was named Corporate Secretary in 2007, and has served as Vice President, General Counsel & Corporate Secretary since 2011. She was named as an executive officer in 2013. Ms. Barnes is responsible for all legal affairs of the company including but not limited to all contract negotiations, SEC compliance, corporate governance, IP strategy and management, licensing transactions, government contract management and dispute resolution. She graduated magna cum laude from Cumberland School of Law in 1997 and is a member of Curia Honoris, scholar of merit. Ms. Barnes received her B.S. in Natural Science with a concentration in biology and chemistry from UAB. Prior to joining the Company, Ms. Barnes worked for the UAB Research Foundation where she managed intellectual property, negotiated license transactions and facilitated the emergence of new companies based on university technology. Prior to employment at the UAB Research Foundation Ms. Barnes practiced corporate law with a prominent law firm in Birmingham, Alabama. Currently, she serves on the Board of the Biotechnology Association of Alabama and has served as a mentor for Alabama Launchpad, a competition created to fuel the development of companies in Alabama.

Fred Cohen

Dr. Fred E. Cohen, M.D., Ph.D., has been appointed as Director of BioCryst Pharmaceuticals, Inc., effective July 23, 2013. In 2001, Dr. Cohen joined TPG to initiate TPG’s venture efforts in biotechnology and life sciences, and he serves as a Partner and Managing Director at TPG Biotech. Dr. Cohen has been a member of the faculty of University of California, San Francisco (UCSF) since 1986. At UCSF, Dr. Cohen has served as an Internist for hospitalized patients, a consulting Endocrinologist and as the Chief of the Division of Endocrinology and Metabolism. His research interests include structure based drug design, prion diseases, computational biology and heteropolymer chemistry. Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. Dr. Cohen was elected to the Institute of Medicine of the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2008. Currently Dr. Cohen serves on the Board of Directors of Genomic Health, Quintiles Transnational and the Boards of several privately held companies.

Robert Ingram

Mr. Robert A. Ingram is an Director of the Company. Bob Ingram joined Hatteras Venture Partners as a General Partner in January 2007. He began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO and Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline (GSK) and served as Vice Chairman Pharmaceuticals of GSK until January 1, 2010. Bob serves as Lead Director of Valeant Pharmaceuticals International and Cree, Inc., and is Chairman of Viamet. He is also a member of the Board of Directors of Regeneron Pharmaceuticals, Inc. Bob graduated from Eastern Illinois University with a B.S. degree in Business Administration. In addition to his professional responsibilities, Bob formed and chaired the CEO Roundtable on Cancer at the request of former President George H.W. Bush, and he is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. Bob is a member of the boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation. He serves as Chairman of the Research Triangle Foundation of North Carolina and is on the Advisory board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California

Sanj Patel

Mr. Sanj K. Patel is Director of BioCryst Pharmaceuticals, Inc. Sanj Patel formed Synageva in June 2008 and was its President & Chief Executive Officer through the company's $8.4 billion acquisition by Alexion Pharmaceuticals in June 2015. While at Genzyme Corporation from 1999 through June 2008, Sanj held leadership roles of increasing responsibility, including Vice President, Head of Sales, Marketing & Commercial Operations. He is the Chairman and CEO of Kiniksa Pharmaceuticals, a privately-held biotechnology company.

Stanley Erck

Mr. Stanley C. Erck is an Independent Director of Biocryst Pharmaceuticals Inc. Stanley was appointed to the Board in December 2008. Mr. Erck has over 15 years of executive leadership experience in the pharmaceutical industry. Mr. Erck has served as President, CEO and Director of Novavax, Inc., a publicly traded biopharmaceutical company since 2011, having previously served as Executive Chairman from 2010 to 2011, and he has served as a director of Novavax since 2009. From 2000 through 2008, Mr. Erck served as President and Chief Executive Officer of Iomai Corporation, a biopharmaceutical company, taking the company through an initial public offering and a merger with Intercell AG, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, Inc., a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics Inc. (now Genzyme Corp.), and in management positions within Baxter International Inc. In addition to Novavax, Mr. Erck currently sits on the board of directors of MaxCyte, Inc. and MdBio Foundation. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.

Nancy Hutson

Dr. Nancy J. Hutson, Ph.D., is an Independent Director of BioCryst Pharmaceuticals, Inc. She was appointed to the Board in January 2012. Dr. Hutson brings over 30 years of experience as a seasoned professional and leader within the pharmaceutical industry. She retired from Pfizer, Inc. in 2006 after spending 25 years in several research and leadership positions, most recently serving as Senior Vice President of Global Research & Development (R&D) as well as Director of Pfizer’s pharmaceutical R&D site, Groton/New London Laboratories. Dr. Hutson received a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. in physiology from Vanderbilt University. Dr. Hutson currently serves on the Board of Directors for Cubist Pharmaceuticals, Inc. and Endo Pharmaceuticals Holdings, Inc. She also previously served on the Board of Directors of Inspire Pharmaceuticals, Inc. In addition, she is an active member on the Board of Directors for Planned Parenthood of Connecticut. Dr. Hutson is also involved in several professional societies, including but not limited to the American Association for the Advancement of Science and the American Physiological Society.

Kenneth Lee

Mr. Kenneth B. Lee, Jr., is an Independent Director of Biocryst Pharmaceuticals Inc. Mr. Lee was appointed to the Board in June 2011. Mr. Lee has over 35 years of experience counseling management teams, boards of directors and investors of technology-based companies worldwide. He is currently a General Partner with Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies, which he joined in 2003. Previously he was President of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young LLP, where he was most recently Managing Director of the firm’s health sciences corporate finance group. Mr. Lee received a Bachelor of Arts degree from Lenoir-Rhyne College and an MBA from the University of North Carolina at Chapel Hill. Mr. Lee is currently an active member on the board of directors of biotech companies Maxygen and Pozen, Inc., as well as the North Carolina Biosciences Organization (“NCBIO”) and iBiliti, a North Carolina based medical device support organization. Previously, Mr. Lee served on the boards of Abgenix, Inc., CV Therapeutics, Inspire Pharmaceuticals, OSI Pharmaceuticals and A.M. Pappas & Associates. He has served in various leadership capacities on these boards, including Chairman of the Board, Independent Lead Director and Chairman of Audit and Compensation Committees.

Rob Bennett

Basic Compensation